Core Viewpoint - The recent strategic collaboration and licensing agreement between the company and AstraZeneca for the development of innovative long-acting peptide drugs has led to a nearly 5% increase in the company's stock price, reflecting strong market confidence in the partnership [1] Group 1: Strategic Collaboration - The company has signed a strategic cooperation and licensing agreement with AstraZeneca, which is expected to enhance its global positioning in long-acting peptide drugs [1] - The transaction amount for this collaboration exceeds expectations, indicating AstraZeneca's high recognition and long-term confidence in the company's long-acting peptide and AI pharmaceutical technology platform [1] Group 2: Technology and Innovation - The collaboration focuses on the company's proprietary sustained-release drug delivery technology platform and peptide drug AI discovery platform, which can achieve sustained release of peptide drugs [1] - The AI discovery platform allows for rapid design and screening of candidate molecules targeting drug sites, with systematic optimization across efficacy, selectivity, and signaling bias [1]
港股异动 | 石药集团(01093)再涨近5% 公司与阿斯利康合作再升级 有望加速长效多肽药物全球布局